Synthesis and biological properties of two dimeric forms of human α-atrial natriuretic peptide  by Kambayashi, Yoshikazu et al.
Volume 206, number 2 PEBS 4085 October 1986 
Synthesis and biological properties of two dimeric forms of 
human a-atria1 natriuretic peptide 
Yoshikazu Kambayashi, Tomoji Kawabata, Seijiro Hara, Akira Yamauchi, Akira Ueda, 
Masao Kono, Masami Doteuchi, Masuhisa Nakamura and Ken Inouyet 
Shionogi Research Laboratories, Shionogi & Co., Ltd., Fukushima-ku, Osaka 553, Japan 
Received 30 July 1986 
Two dimeric forms of human a-atria1 natriuretic peptide (a-ANP) were synthesized by solution methods 
and compared with monomeric a-ANP in terms of some biological and immunochemical properties. The 
parallel form @‘-ANP) and the antiparallel form (B-ANP) were equipotent in smooth muscle relaxant activ- 
ity in isolated rat aorta and their ED,, values were estimated to be 1.7 x lo-* M and 1.6 x 10e8,M, respective- 
ly. Diuretic and natriuretic responses induced by fi-ANP and ,Y’-ANP in anesthetized rats were equally less 
potent but exhibited a significantly longer duration than those induced by a-ANP. fi-ANP and /3’-ANP pos- 
sessed immunoreactivities of 6&100% and S&90% (a-ANP, 100% on a molar basis), respectively, with three 
different antisera raised against cc-ANP-related peptides. 
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1. INTRODUCTION 
Since a potent diuretic-natriuretic activity was 
observed in extracts derived from rat atria [l], 
multiple forms of ANP have been isolated from rat 
atria [2-81 and three distinct forms of ANP have 
been found in the human atrium [9,10]. Of the 
three forms of human peptide, cr-ANP is a 
28-amino acid peptide with an intramolecular 
t To whom correspondence should be addressed 
Abbreviations: Acm, acetamidomethyl; ANP, atria1 
natriuretic peptide; Bzl, benzyl; CM, carboxymethyl; 
Deb, 2,bdichlorobenzyl; DCC, dicyclohexylcarbodi- 
imide; EDC, l-ethyl-3-(3-dimethylaminopropyl)carbodi- 
imide; HOBt, l-hydroxybenzotriazole; HOSu, N-hy- 
droxysuccinimide; HPLC, high-performance liquid 
chromatography; Mob, 4-methoxybenzyl; Pat, phena- 
cyl; Tee, 2,2,2,-trichloroethyl; TFA, trifluoroacetic 
acid; Tos, tosyl; TPCK, L-1-tosylamido-2-phenylethyl 
chloromethylketone 
disulfide linkage [9]. y-ANP is a large peptide 
comprising 126 amino acid residues and contains 
the cu-ANP sequence at the carboxyl end of the 
molecule [lo]. Both a-ANP and y-ANP molecules 
seem to be derived from a common 15 l-residue 
precursor [l 11, while &ANP has been reported to 
be an antiparallel dimer of a-ANP [lo]. The origin 
and mechanism of the formation of &ANP are 
still unknown. Such a dimeric form of ANP has 
not been found in other mammalian species. 
Kangawa et al. [lo] reported that diuretic- 
natriuretic responses to fl-ANP showed a slower 
onset and longer duration than that to CX-ANP or 
y-ANP in the rat. These interesting features of ,&- 
ANP prompted us to study the two dimeric forms 
of cu-ANP. We report here the synthesis of the 
human a-ANP dimers and their biological and im- 
munochemical properties. The parallel and an- 
tiparallel dimers of c~-ANP are tentatively 
designated as 8’ -ANP and @ANP, respectively, in 
this communication. 
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2. MATERIALS AND METHODS 
2.1. Materials 
Human a-ANP, cr-ANP-(7-28), and cu-ANP- 
(17-28) were synthesized in these laboratories. 
Human a-ANP was also obtained from the Pep- 
tide Institute, Osaka, Japan. Aminopeptidase M 
(EC 3.4.11.2) was purchased from Pierce and 
TPCK-treated trypsin (EC 3.4.21.4) from Wor- 
thington. 
2.2. Peptide synthesis 
Protected octacosapeptides (5 and 6) corre- 
sponding to the total amino acid sequence of LY- 
ANP were synthesized by the conventional solu- 
tion methods as shown in fig.lA. An equimolar 
mixture of 5 and 6 was treated with HF at 0°C for 
60 min in the presence of anisole and methionine, 
followed by air-oxidation at pH 6.5 and 25°C. The 
resulting material was purified on a CM-cellulose 
(Whatman CM-52) and a reversed-phase (Wako 
RQ-2) column in the usual manner. Finally 
reversed-phase HPLC was carried out repeatedly 
on a Nucleosil 5Crs column (150 mm x 4.6 mm 
ID) using 26% acetonitrile in 0.1% TFA to 
separate three components (fig.lB), [Cys(Acm)‘, 
Cys(Acm)“]-fi’ -ANP (7)s [Cys(Acm)23, 
Cys(Acm)23’]-fl’-ANP (8), and [Cys(Acm)‘, 
Cys(Acm)23’]-fl-ANP (9), in their pure forms. For 
removal of the Acm groups [12] and concomitant 
oxidation, compound 9 was treated with iodine 
(45 mol/mol peptide) in 90% acetic acid at 23°C 
for 3 h in the presence of methionine (20 mol/mol 
peptide). After addition of ascorbic acid to quench 
the excess iodine, the mixture was evaporated in 
vacua and the residue was subjected to HPLC with 
26% acetonitrile in 0.1% TFA to give P-ANP in 
sufficient purity. In the same manner, fl’-ANP 
was obtained from 8. 
2.3. Bioassays 
2.3.1. In vitro smooth muscle relaxant activity 
The assay was performed using spiral strips of 
isolated rat thoracic aorta suspended in a Krebs 
bicarbonate solution (95% 02 and 5% CO2) at 
37°C. Contraction of the strips was induced with 
50 mM KCl, and the percent relaxation was 
measured for various peptide concentrations, in 
which the relaxation obtained by 0.1 mM 
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papaverine hydrochloride was taken as 100. 
Logarithmic dose-response curves obtained with 
10-10-10-6 M peptide solutions permitted the 
determination of EDso values. 
2.3.2. Diuretic and natriuretic activities 
Male Sprague-Dawley rats (-350 g) were 
anesthetized with sodium pentobarbitaI(30 mg/kg 
i.p.), and then an intrafemoral vein catheter for in- 
fusion and a bladder catheter were installed. The 
animals received a constant infusion of 0.9% NaCl 
at a rate of 0.15 ml/10 min per rat from 30 min 
before a single injection of peptide (0.1 ml/rat 
through the femoral vein catheter) and during the 
evaluation period. Urine was collected through the 
bladder catheter and simultaneous measurements 
of urinary volume [13] and electric conductivity 
were performed automatically. Urinary sodium 
and potassium were measured by flame 
photometry. The data were treated with the paired 
Student’s t-test and given as mean + SE. 
2.4. Radioimmunoassay 
Antisera were produced by immunizing 
Japanese white rabbits in the usual manner with a- 
ANP-(17-28) [14] or human (Y-ANP-(7-28) con- 
jugated to bovine thyroglobulin (Sigma) by the 
carbodiimide method [ 151. ‘251-labelled human cr- 
ANP was prepared by the chloramine T method 
[16] and purified by HPLC. A 0.1 mM phosphate 
buffer (pH 7.0) containing 0.1% bovine serum 
albumin, 1 mM NazEDTA, and 0.01% sodium 
azide was used as the assay buffer. A mixture of 
standard human cu-ANP or sample (0.1 ml), 
human 1251~-ANP (0.1 ml), a properly diluted an- 
tiserum (0.1 ml), and the assay buffer (0.2 ml) in 
polystyrene tubes was incubated at 4°C for 20 h. 
To this were added non-immune rabbit serum 
(1: 20, 0.05 ml) and then second antiserum (goat 
anti-rabbit IgG antiserum, MBL, Nagoya, Japan; 
1: 60, 1 ml) containing 6% polyethyleneglycol 
6000. The mixture was incubated at 4°C for 
60 min to separate bound and free ligands. Cen- 
trifugation at 2OOO x g for 20 min was followed by 
counting the radioactivity of the precipitates. 
3. RESULTS AND DISCUSSION 
In the present synthesis of two dimeric forms of 
human LU-ANP, protected peptides 5 and 6 cor- 
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responding to the 2%amino acid sequence of the 
monomer were built up from four fragments l-4 
(fig. IA). These fragments were synthesized 
basically following a step-by-step strategy, in 
which the two selectively removable sulfhydryl 
protecting groups, Mob and Acm, were used alter- 
natively to protect the two cysteine residues (posi- 
tions 7 and 23 in cu-ANP) as shown in fig.lB. This 
made it possible to form two disulfide crosslinks 
between two molecules of the monomer as desired. 
The resulting dimers ,&ANP and 8 -ANP were 
found to be sufficiently pure by amino acid 
analysis (table 1) and analytical HPLC. HPLC 
separation of cr-ANP, ,&ANP and fl’ -ANP is 
shown in fig.2. 
To confirm the structure of the synthetic pep- 
tides, tryptic digests of ,&ANP and ,&-ANP were 
compared with that of human (Y-ANP in HPLC. 
As shown in fig.3, ,&ANP but not ,&-ANP gave a 
peptide map identical with that derived from cy- 
ANP, clearly indicating that &ANP is the an- 
tiparallel dimer and ,19’-ANP is the parallel dimer 
of wANP, as expected. 
Fig.4 shows the time course of the smooth mus- 
cle relaxant activity in rat aorta at a peptide con- 
centration of 3 x lo-* M. The slower response to 
the dimeric peptides than to the monomer is 
noteworthy. From the data obtained for various 
peptide concentrations (not shown), EDso values 
of a-ANP, &ANP and fl’-ANP were estimated to 
be 8.4 x 10m9 M, 1.6 x IO-* M and 1.7 x lo-* M, 
respectively (IV = 4). 
A 
Boc-Ser(Bzl)-Leu-Arg(Tos)-Arg(Tos)-Ser(Bzl)-Ser(Bzl)-OBzl (1) 
NH2NH2 
Zn/ACOH 
Boc-Cys(R1~-Phe-Gly-Gly-Arg(Tos)-Met-Asp(OBZl~-A~g~Tos~-Ile-Gly-OTce (2) - 
Zn/AcOH 
Em-Ala-Gln-Ser(Bzl)-Gly-Leu-Gly-OPac (3) DCC-HOW 
Boc-Cys(R*~-Asn-Ser(Bzl)-Phe-Arg(Tos)-Tyr(Dcb)-OBzl (4) 
5 or 6 
Bzl Tos Tos Bzl Bzl RL TOS OBzlTos BZl R2 Bzl TOS Deb 
Boc-$er-Leu-drg-~rg-Ber-Qer-C;s-Phe-Gly-Gly-~~g-M~t-~~p-~~g-Il~-Gly-Al~-Gl~-~~~-Gly-L~~-Gly-C~~-A~~-~~~-Ph~-~~g-~y~-OB~l 
5: Rl=Acm, R'=Mob; 6: R1 =Mob, R2 =Ac," 
B AClll Mob Mob ACm 
I 
Boc-1 cys Cys 2+OBzl (5) Boc 1 cys cys 281-OBzl (6) 
7. 23 7 23 
AClll 
""-OH H-11 C;s I;: 281-OH H-,-H 
/ 
H-(1' 
I I 
cys CYS 28' -OH H-(1' cys Cys 28' OH HOj28' Cys cys l'-H 
I 
AClJJ 23' 7' I I AClll ACXll 7' 
(7) (6) (9) 
7’ 23' 23' 7' 
P'-ANP P-ANP 
Fig.1. (A) Synthesis of octacosapeptide derivatives (5 and 6) as intermediates to the parallel dimer (,&‘-ANP) and 
antiparallel dimer (&ANP) of (u-ANP. (B) Schematic illustration of &ANP, /3’-ANP, and their synthetic intermediates. 
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Table 1 
Amino acid ratios in aminopeptidase M digests (APM)a 
and acid hydrolysates (Acid)b of &ANP and fi’-ANP 
Amino /3-ANP fl’ -ANP 
acid 
APM Acid APM Acid 
Asp 2.06(2)’ 4.01(4) 2.04(2) 4.01(4) 
Ser 9.89(14) 7.84(10) 9.92(14) 7.75(10) 
Glu - 2.21(2) - 2.31(2) 
Cit 9.42(10) - 9.00(10) - 
Gly 9.63(10) lO.OO(lO) 9.46(10) lO.Ol(lO) 
Ala 2.18(2) 2.17(2) 2.23(2) 2.23(2) 
(Cys)z 1.74(2) nd 1.57(2) nd 
Met 2.00(2) 2.03(2) 1.96(2) 2.04(2) 
Ile 2.30(2) 2.05(2) 2.36(2) 2.07(2) 
Leu 4.00(4) 4.00(4) 4.00(4) 4.00(4) 
Tyr 2.11(2) 2.01(2) 2.16(2) 2.02(2) 
Phe 3.75(4) 3.99(4) 3.70(4) 4.00(4) 
Arg ndd 9.76(10) 0.72 9.69(10) 
a For enzymatic hydrolysis the peptide (2 nmol) in 
25 mM phosphate buffer (pH 7.0, 40~1) was treated 
with trypsin (2 pg) at 37°C for 3 h and aminopeptidase 
M (2 pg) at 37°C for 21 h, successively. Glutamine and 
asparagine were coeluted with serine. These three 
amino acids were therefore estimated as serine. 
Arginine was mostly converted into citrulline (Cit) 
owing to the presence of an arginine oxidase in the 
enzyme preparation used 
b Acid hydrolysis was performed with 6 M HCl at 110°C 
for 20 h in the presence of phenol 
’ Theoretical values are given in parentheses 
d nd, not determined 
The time courses of diuretic and natriuretic ac- 
tivities of a-ANP and ,&-ANP in rats are shown in 
fig.5. In response to a single injection of (w-ANP 
(1 pg/rat), urinary volume and Na+ excretion im- 
mediately increased to a maximum and then 
decreased to a control level in 20 min. When P- 
ANP (3 pg/rat) was injected, however, the diuretic 
and natriuretic responses appeared more slowly 
and lasted for longer periods of time (fig.5). A 
separate experiment also showed that ,d-ANP 
(3 fig/rat) and p’-ANP (3 pg/rat) had identical 
time courses (not shown). Independent administra- 
tion of cy-ANP (1 pg or 0.3 nmol/rat) or &ANP 
(3 pg or 0.5 nmol/rat) increased urinary volume by 
1.67 k 0.31 ml and 2.47 + 0.39 ml, respectively, 
and Na+ excretion by 263 + 43 pEq and 225 f 
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Fig.2. HPLC separation of a-ANP (l), ,&ANP (2), and 
fl’-ANP (3). Column: Nucleosil SCr8, 150 mm x 
4.6 mm ID; mobile phase: generated by mixing solution 
A (0.1% TFA in water) and solution B (0.1% TFA and 
50% acetonitrile in water), 1.8 ml/min; detection: 
220 nm (range 0.08). The column was eluted with an 
acetonitrile concentration of 20% for 5 min and then 
eluted with a linear gradient of O.S%/min to a final 
concentration of 30%. 
83 pEq, respectively, in 60 min after injection (ZV = 
7). In another experiment, &ANP (3 pg/rat) and 
,~3’-ANP (3 fig/rat) increased urinary output by 
1.59 + 0.37 ml and 1.36 f 0.52 ml, respectively, 
and Na+ excretion by 185 k 53 PEq and 206 f 
55 PEq, respectively, in 60 min after injection (N = 
8). These results indicate that there is no significant 
difference between ,&ANP and fl’-ANP with 
respect to their diuretic-natriuretic activities. ,& 
ANP and fl’ -ANP seem to be somewhat less active 
than CY-ANP when compared on a molar basis, but 
the diuretic and natriuretic responses induced by 
these dimeric forms exhibited a slower onset and 
longer duration than those induced by monomeric 
CY-ANP. Kangawa et al. [lo] have reported that a 
second component of ANP in human atrium 
named ,&hANP [9] is an antiparallel dimer of 
human cu-ANP and induces protracted diuretic- 
natriuretic responses in rats. The general similarity 
of our present observations with those reported by 
Kangawa et al. [lo] strongly suggest hat the syn- 
thetic ,&ANP is identical with natural @hANP. 
The immunoreactivity of ,&ANP and ,&I-ANP 
with ANP-specific antibodies was compared on a 
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A 
:!11.1:;: B 
0 5 10 15 20 25 (mm) 
Fig.3. HPLC profiles of tryptic hy~olysates of cu-ANP 
and its dimers. (A) Blank (no peptide), (B) hydrolysate 
of W-ANP, (C) hydrolysate of &ANP, and (D) 
hydrolysate of fl’-ANP. For HPLC conditions, see the 
legend of fig.2. The column was eluted with a linear 
gradient of acetonitrile concentration from 0 to 50% at 
a rate of 2Sqo/min followed by isocratic elution for 
10 min. Tryptic peptides isolated from peaks T&-2, 
TB*-2 and T&g-3, were found to contain the Cys’-Cysz3’, 
cys’-cys’ ’ , and Cy~~~-Cys~” linkages, respectively. 
Both Tp-1 and Tap-1 contained tyrosine only. 
molar basis with that of CX-ANP using three dif- 
ferent antisera FO45, FO54, and F069 (table 2). 
Although &ANP and fl’ -ANP may have two 
equivalent antigenic sites within their molecules, 
they do not seem to bind more than one antibody 
molecule. This and some conformational dif- 
ferences at or near the antigenic sites may explain 
the different immunoreactivities among ru-ANP, ,& 
ANP, and ,&‘-ANP. 
In the present work we were able to synthesize 
the two dimeric forms of (r-ANP and to show for 
the first time that these dimers were equipotent and 
sig~fi~tly longer-acting than the monomer in 
their diuretic-natriuretic responses, although the 
mechanism of prolongation of action remains to 
be elucidated. 
J 
0 15 30 45 60 
Time (mid 
Fig.4. Time course of smooth muscle relaxant activity of 
(Y-ANP (a), @ANP (a), and B’ -GNP (0) in isolated rat 
aorta (N = 4). Peptide concentration: 3 x IO-* M. 
f 
T 
I I 
-10 0 10 20 30 40 50 60 
Time after injection (mid 
B 
1 
0 ’ I 
-10 0 10 20 30 40 50 60 
Time after injection (min) 
Fig-S. Time course of diuretic and natriuretic activities 
of wANP and @ANP in rats (N = 7). Urine volume (A) 
and Na+ excretion (B) were measured for a-ANP 
(1 pg/rat, light lines) and fi-ANP (3 fig/rat, bold lines). 
Asterisks represent p < 0.05. 
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Table 2 141 
Crossreactivity of peptides related to human a-ANP as 
estimated with antisera FO45, F054 and F069 
Peptide % crossreactivity (cu-ANP = 100)a 
F054 FO45 F069 
a-ANP 100 100 100 
,&ANP 60 93 59 
fl ’ -ANP 49 88 50 
cu-ANP-(7-28) 100 100 130 
ru-ANP-( 17-28) 98 co.3 41 
a Calculated from peptide concentrations yielding 50% 
displacement of ‘*‘I_cy-ANP on a molar basis 
F054 is an antiserum raised against an (u-ANP-(17-28)- 
bovine thyroglobulin conjugate and recognizes the C- 
terminal portion of the cu-ANP molecule. F045 and F069 
are antisera raised against a human cu-ANP-(7-28) 
conjugate. F045 mainly recognizes the ring structure, 
while F069 recognizes almost the whole molecule of 
(Y-ANP-(7-28) 
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